文献速递浆细胞疾病

达雷妥尤单抗治疗系统性AL淀粉样变性:预后因素及肾病范围蛋白尿的不良结局

Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
PubMed 文献 · Blood · 2020-01-01

该研究分析168例晚期系统性AL淀粉样变性患者,接受达雷妥尤单抗/地塞米松(DD,n=106)或达雷妥尤单抗/硼替佐米/地塞米松(DVD,n=62)治疗。DD组3个月缓解率64%、非常好的血液学缓解率48%,中位血液学无事件生存期11.8个月,中位总生存期25.6个月;DVD组分别为66%、55%、19.1个月,中位总生存期未达到。多变量分析显示dFLC>180 mg/L和肾病范围蛋白尿(ACR>220 mg/mmol)为不良预后因素。

要点

  • 达雷妥尤单抗方案在晚期AL淀粉样变性中诱导高血液学缓解率。
  • dFLC>180 mg/L是强的整体不良预后因素。
  • 肾病范围蛋白尿(ACR>220 mg/mmol)显著降低血液学无事件生存期。

核心结论

  • 达雷妥尤单抗挽救治疗在晚期AL淀粉样变性中疗效良好,缓解率挑战现有任何疗法。
  • 预后受浆细胞疾病活动度(dFLC)和肾病范围蛋白尿(ACR)的不良影响。

研究设计与样本

  • 连续系列168例晚期系统性AL淀粉样变性患者,接受DD(n=106)或DVD(n=62)治疗。

主要发现

  • DD组3个月缓解率64%,非常好的血液学缓解率48%,中位血液学无事件生存期11.8个月,中位总生存期25.6个月。
  • DVD组缓解率66%,非常好的血液学缓解率55%,中位血液学无事件生存期19.1个月,中位总生存期未达到。
  • 6个月时心脏器官缓解率DD组22%,DVD组26%。
  • 感染并发症常见(CTC 3/4级:DD 16%,DVD 18%),可能与淋巴细胞减少高发相关(CTC 3/4级:DD 20%,DVD 17%)。
  • 单变量分析:超二倍体和gain 1q21对DD组OS和hemEFS不利,t(11;14)与更好的hemEFS相关;NT-proBNP>8500 ng/L时两种方案均无法克服生存劣势。

临床怎么用

  • 达雷妥尤单抗联合方案可用于晚期AL淀粉样变性的挽救治疗。
  • 评估预后时需关注dFLC水平和肾病范围蛋白尿(ACR)。
  • 治疗期间注意监测感染和淋巴细胞减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab has shown promising first results in systemic amyloid light-chain (AL) amyloidosis. We analyzed a consecutive series of 168 patients with advanced AL receiving either daratumumab/dexamethasone (DD, n = 106) or daratumumab/bortezomib/dexamethasone (DVD, n = 62). DD achieved a remission rate (RR) of 64% and a very good hematologic remission (VGHR) rate of 48% after 3 months. Median hematologic event-free survival (hemEFS) was 11.8 months and median overall survival (OS) was 25.6 months. DVD achieved a 66% RR and a 55% VGHR rate. Median hemEFS was 19.1 months and median OS had not been reached. Cardiac organ responses were noted in 22% with DD and 26% with DVD after 6 months. Infectious complications were common (Common Terminology Criteria [CTC] grade 3/4: DD 16%, DVD 18%) and likely related to a high rate of lymphocytopenia (CTC grade 3/4: DD 20%, DVD 17%). On univariable analysis, hyperdiploidy and gain 1q21 conferred an adverse factor for OS and hemEFS with DD, whereas translocation t(11;14) was associated with a better hemEFS. N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overcome for survival with each regimen. Multivariable Cox regression analysis revealed plasma cell dyscrasia (difference between serum free light chains [dFLC]) >180 mg/L as an overall strong negative prognostic factor. Additionally, nephrotic-range albuminuria with an albumin-to-creatinine-ratio (ACR) >220 mg/mmol was a significantly adverse factor for hemEFS (hazard ratio, 2.1 and 3.1) with DD and DVD. Daratumumab salvage therapy produced good results and remission rates challenging any therapy in advanced AL. Outcome is adversely influenced by the activity of the underlying plasma cell dyscrasia (dFLC) and nephrotic-range albuminuria (ACR).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020. PMID: 32107537. doi:10.1182/blood.2019003633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。